WO2006128740A3 - Methodes et therapies anti-vasculaires utilisant des inhibiteurs de lysyl oxydase - Google Patents

Methodes et therapies anti-vasculaires utilisant des inhibiteurs de lysyl oxydase Download PDF

Info

Publication number
WO2006128740A3
WO2006128740A3 PCT/EP2006/006692 EP2006006692W WO2006128740A3 WO 2006128740 A3 WO2006128740 A3 WO 2006128740A3 EP 2006006692 W EP2006006692 W EP 2006006692W WO 2006128740 A3 WO2006128740 A3 WO 2006128740A3
Authority
WO
WIPO (PCT)
Prior art keywords
lysyl oxidase
oxidase inhibitors
methods
therapies employing
vascular
Prior art date
Application number
PCT/EP2006/006692
Other languages
English (en)
Other versions
WO2006128740A2 (fr
Inventor
Mark Nesbit
Original Assignee
Centelion
Mark Nesbit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centelion, Mark Nesbit filed Critical Centelion
Publication of WO2006128740A2 publication Critical patent/WO2006128740A2/fr
Publication of WO2006128740A3 publication Critical patent/WO2006128740A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des compositions pharmaceutiques et des méthodes de traitement de maladies liées à l'angiogenèse, telles que le cancer. Plus spécifiquement, l'invention concerne une composition comprenant un inhibiteur de lysyl oxydase seul ou en combinaison avec au moins un agent chimiothérapeutique, ainsi que l'utilisation de la composition et/ou de la combinaison dans le traitement d'une maladie liée à l'angiogenèse, telle que le cancer.
PCT/EP2006/006692 2005-06-02 2006-06-02 Methodes et therapies anti-vasculaires utilisant des inhibiteurs de lysyl oxydase WO2006128740A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68640605P 2005-06-02 2005-06-02
US60/686,406 2005-06-02

Publications (2)

Publication Number Publication Date
WO2006128740A2 WO2006128740A2 (fr) 2006-12-07
WO2006128740A3 true WO2006128740A3 (fr) 2007-04-12

Family

ID=37482014

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/006692 WO2006128740A2 (fr) 2005-06-02 2006-06-02 Methodes et therapies anti-vasculaires utilisant des inhibiteurs de lysyl oxydase

Country Status (1)

Country Link
WO (1) WO2006128740A2 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168180B2 (en) 2002-11-27 2012-05-01 Technion Research & Development Foundation Ltd. Methods and compositions for modulating angiogenesis
US8927700B2 (en) 2009-08-21 2015-01-06 Gilead Biologics, Inc. Catalytic domains from lysyl oxidase and LOXL2
US9107935B2 (en) 2009-01-06 2015-08-18 Gilead Biologics, Inc. Chemotherapeutic methods and compositions
US9176139B2 (en) 2007-08-02 2015-11-03 Gilead Biologics, Inc. LOX and LOXL2 inhibitors and uses thereof

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL184627A0 (en) 2007-07-15 2008-12-29 Technion Res & Dev Foundation Agents for diagnosing and modulating metastasis and fibrosis as well as inflammation in a mammalian tissue
CN113321743B (zh) * 2021-07-02 2022-10-21 海南精准医疗科技有限公司 一种靶向赖氨酰氧化酶1的嵌合抗原受体及其用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002011667A2 (fr) * 2000-08-08 2002-02-14 Technion Research And Development Foundation Ltd. Procedes et compositions pharmaceutiques permettant de moduler l'angiogenese
US20030114410A1 (en) * 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
WO2004037992A2 (fr) * 2002-10-23 2004-05-06 Exelixis, Inc. Gene mapk7 en tant que modulateur de la morphogenese de ramification, et procedes d'utilisation
WO2005038465A2 (fr) * 2003-10-07 2005-04-28 Centelion Methodes antivasculaires et antiproliferation, therapies et combinaisons mettant en application des inhibiteurs specifiques de tyrosine kinase

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002011667A2 (fr) * 2000-08-08 2002-02-14 Technion Research And Development Foundation Ltd. Procedes et compositions pharmaceutiques permettant de moduler l'angiogenese
US20030114410A1 (en) * 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
WO2004037992A2 (fr) * 2002-10-23 2004-05-06 Exelixis, Inc. Gene mapk7 en tant que modulateur de la morphogenese de ramification, et procedes d'utilisation
WO2005038465A2 (fr) * 2003-10-07 2005-04-28 Centelion Methodes antivasculaires et antiproliferation, therapies et combinaisons mettant en application des inhibiteurs specifiques de tyrosine kinase

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GOLDBRUNNER R H ET AL: "MODELS FOR ASSESSMENT OF ANGIOGENESIS IN GLIOMAS", JOURNAL OF NEURO-ONCOLOGY, KLUWER, BOSTON, US, vol. 50, no. 1/2, October 2000 (2000-10-01), pages 53 - 62, XP009035224, ISSN: 0167-594X *
KIRSCHMANN DAWN A ET AL: "A molecular role for lysyl oxidase in breast cancer invasion", CANCER RESEARCH, vol. 62, no. 15, 1 August 2002 (2002-08-01), pages 4478 - 4483, XP002414351, ISSN: 0008-5472 *
KLAUBER N ET AL: "INHIBITION OF ANGIOGENESIS AND BREAST CANCER IN MICE BY THE MICROTUBULE INHIBITORS 2-METHOXYESTRADIOL AND TAXOL", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 57, no. 1, 1 January 1997 (1997-01-01), pages 81 - 86, XP000982726, ISSN: 0008-5472 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168180B2 (en) 2002-11-27 2012-05-01 Technion Research & Development Foundation Ltd. Methods and compositions for modulating angiogenesis
US9176139B2 (en) 2007-08-02 2015-11-03 Gilead Biologics, Inc. LOX and LOXL2 inhibitors and uses thereof
US9107935B2 (en) 2009-01-06 2015-08-18 Gilead Biologics, Inc. Chemotherapeutic methods and compositions
US9289447B2 (en) 2009-01-06 2016-03-22 Gilead Biologics, Inc. Chemotherapeutic methods and compositions
US8927700B2 (en) 2009-08-21 2015-01-06 Gilead Biologics, Inc. Catalytic domains from lysyl oxidase and LOXL2

Also Published As

Publication number Publication date
WO2006128740A2 (fr) 2006-12-07

Similar Documents

Publication Publication Date Title
WO2007064931A3 (fr) Derives substitues de 4-amino-pyrrolotriazine utiles dans le traitement de troubles hyperproliferatifs et de maladies associees a l'angiogenese
WO2007103719A3 (fr) MODULATEURS DE LA 11-β-HYDROXYSTÉROÏDE DÉSHYDROGÉNASE DE TYPE 1, LEURS COMPOSITIONS PHARMACEUTIQUES ET LEURS PROCÉDÉS D'UTILISATION
WO2007011962A3 (fr) Traitement du cancer
WO2008033562A3 (fr) Composés inhibiteurs de kinases
WO2008028965A3 (fr) Inhibiteurs de la protéine phosphatase 1, de gadd34 et du complexe protéine phosphatase 1/gadd34, leur préparation et leurs applications
MY191349A (en) New pharmaceutical compositions for the treatment of hyper-proliferative disorders
TW200745124A (en) Azepinoindole derivatives as pharmaceutical agents
WO2007101224A3 (fr) Inhibiteurs de la reponse aux proteines non depliees et procedes d'utilisation
WO2006091395A3 (fr) Inhibiteurs d'activite d'akt
WO2005004818A3 (fr) Composes heterocycliques et leur utilisation comme agents anticancereux
WO2006133955A8 (fr) Compositions contenant adamts13, presentant une activite thrombolytique
WO2007109279A3 (fr) Composes de tetrahydropyridothienopyrimidine et leurs procedes d'utilisation
WO2008030883A3 (fr) Traitement du cancer
WO2007016338A3 (fr) Utilisation d’inhibiteurs de la chk2 kinase pour le traitement du cancer
WO2007106537A3 (fr) Aminoquinolones utilisées comme inhibiteurs de la gsk-3
WO2006110638A3 (fr) Inhibiteur de l'activite akt
WO2006116221A3 (fr) Nouvelles combinaisons therapeutiques pour le traitement ou la prevention de troubles psychotiques
WO2010059004A3 (fr) Composé pouvant empêcher la liaison p53-snail, et agent thérapeutique contre le cancer contenant ce composé en tant que principe actif
WO2006020680A3 (fr) Composes heterocycliques comme agents pharmaceutiques
WO2007002836A3 (fr) Procedes et compositions pour la prevention et le traitement de maladie renale
WO2007067519A3 (fr) Utilisation de neurotransmetteurs et de neuropeptides pour le traitement de maladies de secheresse oculaire et de conditions associees
WO2008125116A3 (fr) Inhibition de l'u-par
WO2006096759A3 (fr) Methodes et compositions destinees a traiter le cancer
WO2008042480A3 (fr) Inhibiteurs époxyde de cystéine protéases
AP2413A (en) 5-phenyl-pentanoic acid derivatives as matrix metalloproteinase inhibitors for the treatment of asthma and other disease.

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06762498

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 06762498

Country of ref document: EP

Kind code of ref document: A2